Ekam Mehat

Ekam Mehat is CTO of REGEN and studies computer science at the University of Washington. Ekam writes REGEN's research coverage on peptides and biomarkers: what the published trials measured, how large the effect was, and where the evidence stops. Every quantitative claim is cited to a primary source, and nothing here is a protocol or a recommendation.